OncoMatch/Clinical Trials/NCT05640999
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Is NCT05640999 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for endometrial cancer.
This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/RAINBO BLUE: POLE-mutated EC * EN10.B/TAPER: p53 wildtype / NSMP EC
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Biomarker criteria
Required: POLE mutation
Required: TP53 wild-type
Disease stage
Required: Stage I, II, III
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: surgery
surgery consisting of hysterectomy and bilateral salpingo-oophorectomy
Cannot have received: neoadjuvant chemotherapy
Prior Neoadjuvant chemotherapy for current endometrial cancer diagnosis
Cannot have received: pelvic radiation
Prior pelvic radiation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sarasota Memorial Health Care Centre · Sarasota, Florida
- Alaska Womens Cancer Care · Anchorage, Alaska
- University of Arizona Cancer Center · Tucson, Arizona
- Cedars-Sinai Medical Center · Los Angeles, California
- Huntington Memorial Hospital · Pasadena, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify